## Accepted Manuscript

Polycystic Ovary Syndrome In Men

Philip R. Cohen, Razelle Kurzrock


PII: S0306-9877(16)30801-5

DOI: http://dx.doi.org/10.1016/j.mehy.2017.04.010

Reference: YMEHY 8535

To appear in: Medical Hypotheses

Received Date: 30 October 2016 Accepted Date: 19 April 2017



Please cite this article as: P.R. Cohen, R. Kurzrock, Polycystic Ovary Syndrome In Men, *Medical Hypotheses* (2017), doi: http://dx.doi.org/10.1016/j.mehy.2017.04.010

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **ACCEPTED MANUSCRIPT**

Polycystic Ovary Syndrome In Men

Philip R. Cohen, MD [1] and Razelle Kurzrock, MD [3]

[1] Department of Dermatology, University of California San Diego, San Diego, California, and [2] Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego Moores Cancer Center, San Diego, California

**Short Title:** Polycystic Ovary Syndrome In Men

**Key Words:** men, ovary, polycystic, syndrome, women

**Word Count:** 315 (text and references)

**Acknowledgements:** This project was supported in part by the Joan and Irwin Jacobs Fund.

#### **Conflict of interest:**

Philip R. Cohen, MD has no financial and no personal relationships with other people or organizations that could inappropriately influence (bias) this work. His employment has no potential conflicts of interest with this work. He has no consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Razelle Kurzrock has research funds from Genentech, Merck Serono, Pfizer, Guardant, Foundation Medicine, and Sequenom, consultant fees from Sequenom, and an ownership interest in Novena, Inc. and Cure Match, Inc. Philip R. Cohen has no conflicts.

This project was supported in part by the Joan and Irwin Jacobs Fund. There are no sponsors involved in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.

#### **Correspondence to:**

Philip R. Cohen, MD 10991 Twinleaf Court San Diego, CA 92131-3643 713-628-5143 (telephone) mitehead@gmail.com (email)

PCOS in Men-Medical Hypotheses Submission 10-30-16

### Download English Version:

# https://daneshyari.com/en/article/5548444

Download Persian Version:

https://daneshyari.com/article/5548444

<u>Daneshyari.com</u>